Specify a stock or a cryptocurrency in the search bar to get a summary
Context Therapeutics Inc
CNTXContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Address: 2001 Market Street, Philadelphia, PA, United States, 19103
Analytics
WallStreet Target Price
7.38 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CNTX
Dividend Analytics CNTX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CNTX
Stock Valuation CNTX
Financials CNTX
Results | 2019 | Dynamics |